CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
0.59 mg Fluocinolone Acetonide implantdrug
Likely dose
0.59 mg Fluocinolone Acetonide implantfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00543296
NCT00543296Phase 4Completed
CompareCT.gov

Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

Duke University·interventional·Posted Oct 12, 2007·Updated Mar 31, 2015

In Brief

A Phase 4 clinical trial evaluating 0.59 mg Fluocinolone Acetonide implant for Uveitis. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of this study is to collect data on patients with severe uveitis that have required re-implantation of the sustained-release fluocinolone drug delivery device due to depletion of study drug in their previous implanted device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
CountriesUnited States
CollaboratorsBausch & Lomb Incorporated

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 12, 2007
Enrollment StartMar 1, 2004
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.7 years ago

Interventions

0.59 mg Fluocinolone Acetonide implantdrug

0.59 mg Fluocinolone Acetonide implant